10.6
Drug Dissolution: Requirements and Profile Comparison
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period…
Dissolution profile data is accepted based on Q values or the percentage of drug dissolved within a given time.
The dissolution testing is done in three stages.
A drug passes the stage 1 test if all six dosage units are ≥ Q + 5%; otherwise, it goes to the second stage.
Here, the average of twelve units must be ≥ Q, and no unit should be < Q - 15%; if not, it proceeds to the final stage.
The final stage requires an average of twenty-four units to be ≥ Q, with no more than 2 units < Q - 15% and none < Q - 25%.
Additionally, dissolution profile comparisons help develop bioequivalent drug products and demonstrate equivalence after formulation changes.
It involves calculating the difference factor, f1, and the similarity factor, f2. Two dissolution profiles are identical if f1 is 0 and f2 is 100.
View the full transcript and gain access to JoVE Core videos
Q1: What is a Q value in drug dissolution testing?
A Q value represents the percentage of drug dissolved within a specified time period and serves as the acceptance criterion for dissolution profile data. Dissolution testing evaluates whether drug dosage units meet or exceed this Q value threshold across three sequential stages, ensuring consistent drug release and bioavailability.
Q2: How does the three-stage dissolution testing process work?
Stage 1 tests six units; all must be ≥ Q + 5% to pass. Stage 2 tests twelve units; their average must be ≥ Q with none < Q - 15%. Stage 3 tests twenty-four units; their average must meet stage 2 criteria with no more than 2 units < Q - 15% and none < Q - 25%. This progressive approach ensures rigorous quality assessment.
Q3: What happens if a drug fails stage 1 dissolution testing?
If any of the six dosage units in stage 1 fall below Q + 5%, the drug proceeds to stage 2 testing, which involves a larger sample of twelve units. This tiered system allows drugs that don't meet the initial strict criteria a second opportunity to demonstrate acceptable dissolution performance.
Q4: What are the difference factor and similarity factor in dissolution profiles?
The difference factor (f1) and similarity factor (f2) quantify differences between two dissolution profiles. Two profiles are identical when f1 equals 0 and f2 equals 100. These factors help demonstrate bioequivalence and assess whether formulation changes maintain equivalent drug release, supporting clinically relevant drug product specifications methods establishment.
Q5: Why are dissolution profile comparisons important in drug development?
Dissolution profile comparisons help develop bioequivalent drug products and demonstrate equivalence after formulation changes. By comparing f1 and f2 values between test and reference products, manufacturers ensure that modifications maintain consistent drug performance and therapeutic effectiveness throughout the product lifecycle.
Q6: What conditions must be met when comparing dissolution profiles between products?
Profile comparisons require a minimum of three dissolution time points measured on twelve drug products for both test and reference cases. At most one mean value exceeding 85% dissolved is allowable per product, and standard deviation of any product should not exceed 10% from the second to final time point.
Q7: How does dissolution testing support bioequivalent drug product development?
Dissolution testing establishes baseline drug release profiles and enables comparison between formulations using f1 and f2 factors. This in vitro drug release testing overview development and validation ensures that generic or reformulated products release drug at rates equivalent to reference products, confirming therapeutic bioequivalence.